In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a decline, ending the day at $7.64 which represents a decrease of $-0.09 or -1.16% from the prior close of $7.73. The stock opened at $7.64 and touched a ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

Evercore ISI raised the firm’s price target on BioCryst (BCRX) to $12 from $10 and keeps an Outperform rating on the shares. The company preannounced 2024 Orladeyo revenue of $437M, $2M ahead of the ...

BioCryst Pharmaceuticals, Inc. (BCRX) stock price is 7.33 and BioCryst Pharmaceuticals, Inc. (BCRX) 10-day simple moving average is 7.67. BioCryst Pharmaceuticals, Inc. (BCRX) stock price is 7.33 ...

BioCryst (NASDAQ:BCRX) released its preliminary 2024 revenue results, along with guidance for 2025. The company said it expects to report 2024 net revenue of $450M, up 36% from the prior year ...